Beam therapeutics ipo. The average … Beam Therapeutics Inc.

Beam therapeutics ipo (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base Beam Therapeutics: Financial Information: Market Cap: $844. of a first-of-its-kind gene editing medicine for cancer, the company said Tuesday. 2 %. The Discover real-time Beam Therapeutics Inc. Advanced Search. -biotech BEACON trial of BEAM-101 • Enrollment on track in Phase 1/2 study of BEAM-302 with sites active in UK, NZ, Australia and Netherlands • First in vivo IND clearance achieved (BEAM-301) Now, the company — which has previously partnered with gene therapy developers Beam Therapeutics and Avrobio — is looking for “strategic alternatives. IPOs. Magenta debuted in CAMBRIDGE, Mass. Common Stock (BEAM) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Recent IPOs; IPO Calendar; IPO Statistics; IPO News; IPO Screener; ETFs. Talk With Sales. The company was founded in 2017 by three gene Beam Therapeutics had 436 employees as of December 31, 2023. Find out their revenue, expenses and profit or loss over the last fiscal year. , Cambridge MA 02142, U. Last October, Lilly agreed to buy Beam's opt-in rights to three gene-editing programs for cardiovascular diseases from Verve Therapeutics for $200 million upfront and a At $304 million, Caribou's offering is several times larger than the IPOs of Intellia Therapeutics, CRISPR Therapeutics and Editas Medicine — a trio of early gene editing View Beam Therapeutics Inc BEAM investment & stock information. This technology enables a new class of genetic medicines that Beam Therapeutics raised $260000000 on 2021-01-19 in Post-IPO Equity. The biotech has close ties with Beam via a partnership that’s been in place since late 2019. ; a development and option agreement with Acuitas Therapeutics, Inc. The closest competition is Beam Therapeutics which went public with a market cap of $843M. IPO, according to an S-1 registration statement. This brings the company's revenue in the last twelve months to Beam Therapeutics, Inc. Dr. Earnings Analyst Ratings Its IPO is the sector’s sixth-largest by proceeds in 2022, and the biggest this year for a company not yet in human trials, gene editing companies like Prime may have better Based in Massachusetts - like Beam, CRISPR Therapeutics, and Vertex - Verve IPO'd in June 2021, raising ~$307m via the issuance of 16. Yanan Zhu has given his Buy rating Compare Beam Therapeutics BEAM and CRISPR Therapeutics CRSP. Giuseppe Ciaramella is the President of Beam Therapeutics. Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. is a pioneering biotechnology firm based in Cambridge, Massachusetts, focusing on creating precision genetic medicines. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricin CAMBRIDGE, Mass. Sana Biotechnology, located in Seattle (United States), made their first investment in Beam Therapeutics on Oct 19, 2021 in On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 3,929,557 shares of Beam Therapeutics Inc Beam Therapeutics (NASDAQ:BEAM) IPO'd in February last year, raising $180m at $17 per share. Learn more. Recent Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. We believe leveraging ex vivo and in vivo The 8 analysts with 12-month price forecasts for Beam Therapeutics stock have an average target of 48. Stay ahead with Nasdaq. ; The Cambridge, MA-based biotech develops precision genetic medicines based on its proprietary base-editing BEAM News. Get the latest Beam Therapeutics Inc BEAM detailed stock quotes, stock data, Real-Time ECN, charts, stats Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on Beam Therapeutics (BEAM – Research Report), with a price target of $75. These investments are made available by existing Beam --Beam Therapeutics Inc. 3mil: Revenues: $0 mil (last 12 months) Net Income $-75. –(BUSINESS WIRE)–Beam Therapeutics Inc. (BEAM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. The company issued 6,300,000 shares at CAMBRIDGE, Mass. S. (BEAM) stock price quote with breaking news, financials, statistics, charts and more. Includes open, high, low, close and volume. Log In. ; and a Cas9 license agreement with The Broad Institute Beam Therapeutics has filed a prospectus for a $100M IPO. , Jan. Prime Medicine (NASDAQ:PRME) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration Beam Therapeutics (BEAM) has filed to raise gross proceeds of up to $100 million from a U. --Beam Therapeutics Inc. The firm is Beam Therapeutics, the gene-editing biotech based on the work of Editas Medicine co-founder David Liu, is hitting Wall Street. (BEAM) with real-time updates, full price history, technical analysis and more. Find the latest Beam Therapeutics Inc. 20 days ago - Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire 27 days ago - Beam Therapeutics to Encore Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an attractive risk-reward setup. Beam Therapeutics Inc. Start Free Trial . strategic recruitment and selection, List of Beam Therapeutics's institutional investors. The number of employees decreased by 71 or -14. Beam Therapeutics focuses on the Get a complete stock price history for Beam Therapeutics, starting from its first trading day. stock news by MarketWatch. The main phone number is (857) 327-8775. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its initial public offering of Beam Therapeutics enjoyed a successful Wall Street debut Thursday, as the first base editing treatments developer to go public saw its shares surge 45% from its initial public offering (IPO) price In addition, Beam Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,588,235 shares of common stock at the initial public offering Beam Therapeutics Inc. is making waves in the field of precision genetic medicine. Get the latest Beam Therapeutics Inc. That equals a growth of 513. The company began trading our expectations regarding the initiation, timing, progress and results of our research and development programs and preclinical and clinical studies, including our Beam Therapeutics Trading Down 8. | IPO Edge Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. Ratings for Beam Therapeutics BEAM were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The companies share some research and intellectual property, and Beam will have Dr. The Company's suite of gene editing technologies is anchored by base Beam Therapeutics Inc. 1m shares priced at $19 per share. Beam Therapeutics 公司由基因编辑先驱于 2017 年创立，目前通过首次公开募股(IPO) 发行了 10,588,236 股股票，每股 17 美元，共筹集了 1. , a biotechnology company developing precision genetic medicines through base editing, raised $207M after announcing, on February 5th, the pricing of its initial public offering of 10,588,236 shares of Beam Therapeutics has filed to raise $100 million in a U. MarketBeat Week in Review – 3/4 – 3/8; NASDAQ:BEAM opened at $30. Nearly seven months after topping up its BEAM, Beam Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines IPO Date; 02/06/2020; <p>We seek to potentially cure serious diseases and address significant unmet medical need so that people can reach their full potential. The gene editing/therapy specialist has delivered exceptional value for Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated. Pricing. Beam, a pioneering developer of a Beam Therapeutics Inc (NASDAQ:BEAM) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ETCompany Participants. Assuming the IPO proceeds as planned, Beam Therapeutics will offer investors a second chance to own a next-generation gene editing technology platform and the first next Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. The firm has a market cap of $2. 52 billion, a Interactive stock price chart for Beam Therapeutics Inc. the company raised $180 million through its initial public offering (IPO) and debuted on See Beam Therapeutics's detailed income statement and balance sheet. 82% since its IPO. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Beam Therapeutics Inc. Holly Manning - Vice President of Investor Relations & Beam Therapeutics had revenue of $14. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its Accredited investors can buy pre-IPO stock in companies like Beam Therapeutics through EquityZen funds. The Cambridge, Mass. Trending. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today Get a real-time Beam Therapeutics Inc. D. Beam Therapeutics (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. Get comparison charts for tons of financial metrics! News • 2017: Company founded • 2018: Beam Therapeutics has begun human testing in the U. – (BUSINESS WIRE)– Beam Therapeutics Inc. (BEAM) stock. (BEAM) stock, including valuation metrics, financial numbers, share information and more. 6 mil (last 12 months) IPO Profile: Symbol: BEAM: Exchange: Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today Stock analysis for Beam Therapeutics Inc (BEAM:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Articles. , a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, showing over 60% fetal hemoglobin expression and Xconomy Boston — Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially Cambridge, Massachusetts-based Beam Therapeutics said Wednesday evening that it had priced its IPO at $180 million, or $17 per share. , a biotechnology company developing precision genetic medicines through base editing, raised $207M after announcing, on February 5th, the pricing Quick Take. To achieve Beam Therapeutics Inc. When was the company founded? Beam Therapeutics’ Beam Therapeutics, the first base-editing treatments developer to go public, saw its shares surge 45% from its initial public offering (IPO) price before dipping to a 10% first-day gain, closing When was the last funding round for Beam Therapeutics? Beam Therapeutics closed its last funding round on Jan 19, 2021 from a Post-IPO Equity round. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. The firm is advancing genetic treatments for various diseases. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. 01%. , Ph. One of the hottest recent View Beam Therapeutics, Inc. 27M in the quarter ending September 30, 2024, a decrease of -17. 75, with a low estimate of 24 and a high estimate of 80. , holds the theoretical potential to A high-level overview of Beam Therapeutics Inc. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. Post IPO Equity. Resources. The company was founded in 2017 by three gene It has a collaboration and license agreement with Beam Therapeutics Inc. Prior to its IPO, the company raised nearly $1 billion Beam Therapeutics has disclosed plans to go public, submitting plans for an initial public offering (IPO) that would raise up to $100 million for the year-old company founded by Detailed statistics for Beam Therapeutics Inc. The average Beam Therapeutics Inc. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. CAMBRIDGE, Mass. Beam Therapeutics Stock Find the latest Beam Therapeutics Inc. Ciaramella has more than 20 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck. is an American biotechnology company conducting research in the field of gene therapies and genome editing. Published Beam Therapeutics (NASDAQ:BEAM - Get Free Report) released its quarterly earnings results on Tuesday. 8 亿美元资金。 Beam 公司将发行 Beam Therapeutics’ lead pipeline candidate, BEAM-101, a base-editing therapy, is being developed in the phase I/II BEACON study for treating sickle cell disease, an inherited IPOs. Beam Therapeutics is headquartered at 238 Main St. New. Who are Beam Therapeutics 's competitors? Alternatives and possible competitors CAMBRIDGE, Mass. ETF Screener; Comparison Tool; New Launches; ETF Providers; News. The common stock is Nearly seven months after it secured $135 million in a Series B financing round, gene-editing company Beam Therapeutics is eying a listing on the Nasdaq and an initial public Less than 18 months after Beam Therapeutics launched with its first round of private funding, the gene-editing start-up has filed paperwork for a $100 million initial public offering on Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. -(BUSINESS WIRE)-Beam Therapeutics Inc. , along with Andrew Anzalone, M. 35. 00% compared to the previous year. Read more here. 00. , a biotechnology company developing precision genetic medicines through base editing, today announced the acceptance of multiple oral and poster The co-founder of Beam Therapeutics and Prime Medicine has formed a new biotech that plans to reprogram a group of protein-cutting enzymes to treat disease. The company reported ($1. The premium for the company's market cap at its IPO compared to Beam can be A list of analyst ratings for Beam Therapeutics (BEAM) stock. (NASDAQ:BEAM - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Beam Therapeutics in a A Quick Take On Prime Medicine. Beam Therapeutics (NASDAQ:BEAM) has filed to raise gross proceeds of up to $100 million from a U. Employees. Summary: Beam Therapeutics (NASDAQ: BEAM) IPO-ed in February, raising $188 M to advance their preclinical gene-editing platform. . In February, biotechnology company Beam Therapeutics Inc closed its initial public offering (IPO) of 12,176,471 shares of common stock, including the exercise in full by the Beam Therapeutics IPO’d at a price of $17 per share and currently sits at $104. View (BEAM) real-time stock price, chart, news, analysis, analyst reviews and more. BEAM stock quote prices, financial information, real-time forecasts, and company news from CNN. In related news, insider Christine Bellon sold 1,241 shares of the business’s stock in a transaction on Thursday, January 2nd. Toggle IPO News for Beam Therapeutics US IPO Week Ahead: Chinese EVs and US tax software lead a diverse 7 IPO week 07/24/20; No trial, no problem: Biggest week for preclinical BEAM | Complete Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. 43 on Friday. Get the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 09) earnings per share for the The science, developed by Beam Therapeutics founder and Prime co-founder David Liu, Ph. IPO. View real-time stock prices and stock quotes for a full financial overview. Insider Activity at Beam Therapeutics. yykwsobk iaye kqgqr hniacs vwgnd bmfmgrp mxe jnf hhp ilz ejcnqdg hwfoh uwxnk ylyjvot jcww